PMEL and melanoma: In particular, both in vivo production and the formation of nanoparticles could be necessary to elicit an effective cellular response, as the DLnano-vaccines that were scaffolding immunodominant melanoma Gp100 and Trp2 epitopes were shown to induce more potent and consistent epitope-specific CTL responses than did the corresponding monomeric DNA vaccines (17).